This is called, aptly, obstructive hypertrophic cardiomyopathy. This kind of obstruction is behind many of the more ...

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, ...

Edgewise Therapeutics has announced positive top-line findings from two clinical trials where its EDG-7500 showed benefit as ...

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of ...

Shares of biopharma outfit Edgewise Therapeutics ( EWTX -4.14%) soared more than 50% today, reaching a three-year high ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

This early-stage candidate is being evaluated for the treatment of oHCM and has demonstrated ... unaddressed medical needs in the treatment of HCM. In other recent news, Cytokinetics has reported ...

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...

H.C. Wainwright's reiteration of the Buy rating and the $90 price target for Cytokinetics reflects confidence in the clinical advancement of EDG-7500 and its potential to meet the unaddressed medical ...

Shinhan Life Vietnam supported youngsters undergoing leukemia treatment by providing VNĐ150 million worth of medical expenses ...

Ho Chi Minh City is currently facing a critical shortage of radiopharmaceuticals needed for PET/CT scans, crucial in ...